Eli Lilly & Co (1LLY) Stock Forecast & Price Target

8 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1LLY Analyst Ratings

Strong Buy

20 Buy

2 Hold

1 Sell

Based on 23 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1LLY Stock 12 Month Forecast

Average Price Target

€1,214.60

▲(13.62% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is €1,214.60 with a high forecast of €1,424.59 and a low forecast of €836.95. The average price target represents a 13.62% change from the last price of €1,069.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"686":"€686","1425":"€1,425","870.75":"€870.8","1055.5":"€1,055.5","1240.25":"€1,240.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1424.591472,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.42K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1214.5977853304998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.21K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":836.9474898,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€836.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[686,870.75,1055.5,1240.25,1425],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1023.2,1054.0762670769232,1084.9525341538463,1115.8288012307694,1146.7050683076923,1177.5813353846154,1208.4576024615385,1239.3338695384616,1270.2101366153847,1301.0864036923076,1331.962670769231,1362.8389378461538,1393.715204923077,{"y":1424.591472,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1023.2,1037.9229065638847,1052.6458131277693,1067.368719691654,1082.0916262555384,1096.814532819423,1111.5374393833076,1126.2603459471923,1140.983252511077,1155.7061590749615,1170.4290656388462,1185.1519722027306,1199.8748787666152,{"y":1214.5977853304998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1023.2,1008.8728838307693,994.5457676615385,980.2186514923077,965.8915353230769,951.5644191538462,937.2373029846154,922.9101868153846,908.5830706461538,894.2559544769231,879.9288383076923,865.6017221384616,851.2746059692307,{"y":836.9474898,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":687.839,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":738.319,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":913.178,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":911.586,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":886.905,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":882.423,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":822.113,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":784.032,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":922.195,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1043.323,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":992.196,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1013.6,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1023.2,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€1,425

Average Price Target€1,215

Lowest Price Target€836.95

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emily Field

Barclays

€1,246.52

Buy

16.61%

Upside

Reiterated

10/05/26

Analysts Are Bullish on Top Healthcare Stocks: Lifestance Health Group (LFST), Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

10/01/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Eli Lilly & Co (NYSE: LLY) and Liquidia Technologies (NASDAQ: LQDA)

Trung Huynh

RBC Capital

€1,335.55

Buy

24.93%

Upside

Reiterated

10/01/26

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

Steve Scala

TD Cowen

€1,112.96

Buy

4.11%

Upside

Reiterated

10/01/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Jade Biosciences (NASDAQ: JBIO)

Evan Seigerman

BMO Capital

€1,246.52

Buy

16.61%

Upside

Reiterated

09/30/26

Evan Seigerman Reiterates Buy on Eli Lilly, Citing Strong Obesity/Diabetes Portfolio and Pipeline Momentum, Maintains $1400 Price Target

Asad Haider

Goldman Sachs

€1,217.14→€1,220.7

Buy

14.19%

Upside

Reiterated

09/30/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Eli Lilly & Co (NYSE: LLY)

Chris Schott

J.P. Morgan

€1,246.52→€1,335.55

Buy

24.93%

Upside

Reiterated

09/28/26

Eli Lilly price target raised to $1,500 from $1,400 at JPMorganEli Lilly price target raised to $1,500 from $1,400 at JPMorgan

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

09/23/26

Analysts Conflicted on These Healthcare Names: TriSalus Life Sciences (NASDAQ: TLSI) and Eli Lilly & Co (NYSE: LLY)

Jose Luis Pascual

JLPascual

€921.53

Hold

-13.79%

Downside

Reiterated

09/23/26

Akash Tewari

Jefferies

€1,282.13

Buy

19.94%

Upside

Reiterated

09/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Moderna (NASDAQ: MRNA) and Eli Lilly & Co (NYSE: LLY)

Mohit Bansal

Wells Fargo

€1,184.19

Buy

10.78%

Upside

Reiterated

09/21/26

Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and Eli Lilly & Co (NYSE: LLY)

Seamus Fernandez

Guggenheim

€1,133.44→€1,143.23

Buy

6.94%

Upside

Reiterated

09/17/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)

David Risinger

Leerink Partners

―

Buy

―

Reiterated

09/16/26

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and Eli Lilly & Co (NYSE: LLY)

Kerry Holford

Berenberg Bank

€1,086.25→€1,246.52

Buy

16.61%

Upside

Upgraded

09/14/26

Eli Lilly upgraded to Buy from Hold at BerenbergEli Lilly upgraded to Buy from Hold at Berenberg

Rajesh Kumar

HSBC

€756.81→€836.95

Sell

-21.71%

Downside

Reiterated

09/10/26

Eli Lilly price target raised to $940 from $850 at HSBCEli Lilly price target raised to $940 from $850 at HSBC

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emily Field

Barclays

€1,246.52

Buy

16.61%

Upside

Reiterated

10/05/26

Analysts Are Bullish on Top Healthcare Stocks: Lifestance Health Group (LFST), Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

10/01/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Eli Lilly & Co (NYSE: LLY) and Liquidia Technologies (NASDAQ: LQDA)

Trung Huynh

RBC Capital

€1,335.55

Buy

24.93%

Upside

Reiterated

10/01/26

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

Steve Scala

TD Cowen

€1,112.96

Buy

4.11%

Upside

Reiterated

10/01/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Jade Biosciences (NASDAQ: JBIO)

Evan Seigerman

BMO Capital

€1,246.52

Buy

16.61%

Upside

Reiterated

09/30/26

Evan Seigerman Reiterates Buy on Eli Lilly, Citing Strong Obesity/Diabetes Portfolio and Pipeline Momentum, Maintains $1400 Price Target

Asad Haider

Goldman Sachs

€1,217.14→€1,220.7

Buy

14.19%

Upside

Reiterated

09/30/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Eli Lilly & Co (NYSE: LLY)

Chris Schott

J.P. Morgan

€1,246.52→€1,335.55

Buy

24.93%

Upside

Reiterated

09/28/26

Eli Lilly price target raised to $1,500 from $1,400 at JPMorganEli Lilly price target raised to $1,500 from $1,400 at JPMorgan

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

09/23/26

Analysts Conflicted on These Healthcare Names: TriSalus Life Sciences (NASDAQ: TLSI) and Eli Lilly & Co (NYSE: LLY)

Jose Luis Pascual

JLPascual

€921.53

Hold

-13.79%

Downside

Reiterated

09/23/26

Akash Tewari

Jefferies

€1,282.13

Buy

19.94%

Upside

Reiterated

09/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Moderna (NASDAQ: MRNA) and Eli Lilly & Co (NYSE: LLY)

Mohit Bansal

Wells Fargo

€1,184.19

Buy

10.78%

Upside

Reiterated

09/21/26

Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and Eli Lilly & Co (NYSE: LLY)

Seamus Fernandez

Guggenheim

€1,133.44→€1,143.23

Buy

6.94%

Upside

Reiterated

09/17/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)

David Risinger

Leerink Partners

―

Buy

―

Reiterated

09/16/26

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and Eli Lilly & Co (NYSE: LLY)

Kerry Holford

Berenberg Bank

€1,086.25→€1,246.52

Buy

16.61%

Upside

Upgraded

09/14/26

Eli Lilly upgraded to Buy from Hold at BerenbergEli Lilly upgraded to Buy from Hold at Berenberg

Rajesh Kumar

HSBC

€756.81→€836.95

Sell

-21.71%

Downside

Reiterated

09/10/26

Eli Lilly price target raised to $940 from $850 at HSBCEli Lilly price target raised to $940 from $850 at HSBC

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ZVRAZevra Therapeutics

DFTXDefinium Therapeutics

HITIHigh Tide

DNLIDenali Therapeutics

MDWDMediwound

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months

Louise ChenScotiabank

Success Rate

28/37 ratings generated profit

Average Return

+9.40%

Copying Louise Chen's trades and holding each position for 3 Months would result in 75.68% of your transactions generating a profit, with an average return of +9.40% per trade.

1 Year

Geoff MeachamCiti

Success Rate

40/44 ratings generated profit

Average Return

+41.62%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +41.62% per trade.

2 Years

Carter GouldCantor Fitzgerald

Success Rate

40/42 ratings generated profit

Average Return

+74.00%

Copying Carter Gould's trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +74.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1LLY Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1LLY has received 46 Buy Ratings, 4 Hold Ratings, and 1 Sell Ratings. 1LLY average Analyst price target in the past 3 months is 1,214.60.

Each month's total comprises the sum of three months' worth of ratings.

1LLY Financial Forecast

1LLY Earnings Forecast

Next quarter’s earnings estimate for 1LLY is €8.83 with a range of €8.22 to €10.07. The previous quarter’s EPS was €7.46. 1LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1LLY has Performed in-line its overall industry.

1LLY Sales Forecast

Next quarter’s sales forecast for 1LLY is €19.87B with a range of €19.04B to €21.41B. The previous quarter’s sales results were €20.46B. 1LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1LLY has Performed in-line its overall industry.

1LLY Stock Forecast FAQ

What is IT:1LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,214.60.

What is IT:1LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly & Co has 13.62% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eli Lilly & Co a Buy, Sell or Hold?

Eli Lilly & Co has a consensus rating of Strong Buy, which is based on 20 buy ratings, 2 hold ratings and 1 sell ratings.

What is Eli Lilly & Co’s share price target?

The average share price target for Eli Lilly & Co is 1,214.60. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €1,424.59 ,and the lowest forecast is €836.95. The average share price target represents 13.62% Increase from the current price of €1,069.

What do analysts say about Eli Lilly & Co?

Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of Eli Lilly & Co?

To buy shares of IT:1LLY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Eli Lilly & Co (1LLY) Stock Forecast & Price Target

1LLY Analyst Ratings

1LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

1LLY Analyst Recommendation Trends

1LLY Financial Forecast

1LLY Earnings Forecast

1LLY Sales Forecast

1LLY Stock Forecast FAQ

Detailed List of Analyst Forecasts